Welcome to our dedicated page for Catalyst Pharmaceuticals SEC filings (Ticker: CPRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Catalyst Pharmaceuticals files regulatory disclosures that document material events for its rare-disease biopharmaceutical business and Nasdaq-listed common stock. Recent Form 8-K and 8-K/A filings cover operating results and business updates, Regulation FD presentation materials, press-release exhibits, and capital-structure matters including a board-authorized share repurchase program.
The filings also record company-specific legal and intellectual property disclosures, including FIRDAPSE Orange Book patent litigation, amendments to prior material-event reports, and settlement-related corrections. These documents tie formal disclosures to Catalyst’s commercial products, governance actions, exhibit filings, and public-company reporting obligations.
Catalyst Pharmaceuticals reported topline results from a two-part Phase 1 clinical study of AGAMREE (vamorolone) in healthy adult volunteers. The study showed balanced corticosteroid activity, with expected cortisol suppression and no evidence of significant immunosuppressive activity at clinical doses.
In Part A, vamorolone produced similar cortisol suppression to deflazacort at label-based clinical doses, supporting currently labeled dosing for Duchenne muscular dystrophy. In Part B, even at an ascending dose up to 40 mg/kg/day, which is above currently approved dosing, the data did not indicate clinically meaningful immunosuppression, reinforcing its potential use across a broad range of chronic inflammatory rare diseases.
Catalyst Pharmaceuticals, Inc. reports that the U.S. Federal Trade Commission granted early termination of the Hart-Scott-Rodino antitrust waiting period for its planned acquisition by Angelini Pharma. The merger agreement was signed on May 6, 2026, and Catalyst will become a wholly owned subsidiary of Angelini Pharma if completed.
The transaction still requires adoption of the merger agreement by holders of at least a majority of Catalyst’s outstanding common shares and other customary closing conditions. The parties currently expect the deal to close in the third quarter of 2026, as described in Catalyst’s definitive proxy statement filed with the SEC on June 8, 2026.
Catalyst Pharmaceuticals, Inc. is being acquired by Angelini Pharma for $31.50 per share in cash. Under the Agreement and Plan of Merger dated May 6, 2026, Merger Sub will merge with and into Catalyst, and Catalyst will become a wholly owned subsidiary of Angelini Pharma.
Holders of Catalyst common stock of record as of June 3, 2026 are entitled to vote at a virtual special meeting on July 8, 2026. At the Effective Time, each outstanding share (other than certain excluded or dissenting shares) will convert into the right to receive $31.50 per share, without interest and subject to applicable tax withholding. The Board unanimously recommends stockholder approval and the company currently expects closing in Q3 2026, subject to customary closing conditions and regulatory approvals.
Catalyst Pharmaceuticals Chief Medical Officer William T. Andrews reported routine equity compensation activity involving restricted stock units that convert into common stock. On June 3, 2026, 3,052 restricted stock units were exercised into 3,052 shares of common stock at a conversion price of $0.0000 per share.
Of these, 743 shares were withheld by Catalyst Pharmaceuticals to cover applicable tax obligations, described as a tax-withholding disposition. After this withholding, Andrews directly holds 2,309 shares of common stock. Footnotes explain that each restricted stock unit represents a right to receive one common share upon vesting and that the related derivative securities vest in five equal annual tranches on June 2 of each year from 2026 through 2030.
Catalyst Pharmaceuticals (CPRX) is asking stockholders to approve a merger under which Angelini Pharma will acquire Catalyst and each outstanding share will be converted into the right to receive $31.50 per share in cash. The Board unanimously recommends voting FOR the Merger Proposal, the advisory Compensation Proposal and the Adjournment Proposal. The proxy describes the Merger Agreement dated May 6, 2026, appraisal rights under Delaware law, potential termination fees, and an expected closing in Q3 2026, subject to closing conditions and regulatory approvals. Read the Merger Agreement in Annex A for full terms.
Catalyst Pharmaceuticals reported first quarter 2026 total revenues of $149.4 million, up 5.6% from $141.4 million a year earlier, driven by growth in key rare-disease drugs. Net product revenue from FIRDAPSE rose 18.1% to $98.9 million and AGAMREE revenue jumped 66.6% to $36.7 million, while FYCOMPA declined 61.3% to $13.8 million.
GAAP net income increased to $63.7 million ($0.50 diluted per share), with non-GAAP net income of $100.3 million ($0.79 diluted per share), reflecting margin expansion and lower cost of sales. Cash and cash equivalents reached $755.9 million with no funded debt as of March 31, 2026. The company stated it will not provide forward-looking guidance or host an earnings call for this quarter.
Catalyst Pharmaceuticals reported solid first-quarter 2026 results with continued profitability and strong cash generation. Total revenues were $149.4 million, up from $141.4 million a year earlier, driven by higher FIRDAPSE and AGAMREE sales, partly offset by lower FYCOMPA revenue.
Net income rose to $63.7 million, with diluted earnings per share of $0.50. Operating income reached $73.2 million, supported by disciplined R&D and stable SG&A spending. Cash from operating activities was $59.6 million, lifting cash and cash equivalents to $755.9 million and total assets to $1.15 billion as of March 31, 2026, with minimal debt-like obligations.
The business remains highly concentrated in three rare-disease and neurology products—FIRDAPSE, AGAMREE and FYCOMPA—with one major U.S. distributor accounting for about 90% of product revenue. The company also highlights strong patent and licensing positions, including settlements that delay FIRDAPSE generics into the 2030s. After quarter-end, Catalyst signed a definitive merger agreement to be acquired by Angelini Pharma, which would turn Catalyst into a wholly owned subsidiary, marking a major strategic shift for shareholders.
Catalyst Pharmaceuticals agreed to be acquired by Angelini Pharma in an all-cash deal. Angelini will buy all outstanding Catalyst shares for $31.50 per share, valuing the company at approximately $4.1 billion, a 21% premium to Catalyst’s unaffected April 22, 2026 closing price and a 28% premium to its 30-day average.
A wholly owned Angelini subsidiary will merge into Catalyst, which will become a private, wholly owned subsidiary. The transaction has been unanimously approved by both boards and is expected to close in the third quarter of 2026, subject to a stockholder vote, antitrust clearance and other customary conditions. The merger has no financing condition, with Angelini planning to use cash and debt.
The merger agreement includes a termination fee of about $155.5 million payable by Catalyst to Angelini in specified circumstances, including acceptance of a superior proposal. Catalyst’s directors and executive officers signed voting agreements to support the deal. Separately, Catalyst and SERB settled patent litigation with Hetero over generic FIRDAPSE®, with Hetero barred from U.S. sales of its generic before January 2035, resolving all pending FIRDAPSE patent cases.
Catalyst Pharmaceuticals agreed to be acquired by Angelini Pharma in an all-cash deal. Angelini will buy all outstanding Catalyst shares for $31.50 per share, valuing the company at approximately $4.1 billion, a 21% premium to Catalyst’s unaffected April 22, 2026 closing price and a 28% premium to its 30-day average.
A wholly owned Angelini subsidiary will merge into Catalyst, which will become a private, wholly owned subsidiary. The transaction has been unanimously approved by both boards and is expected to close in the third quarter of 2026, subject to a stockholder vote, antitrust clearance and other customary conditions. The merger has no financing condition, with Angelini planning to use cash and debt.
The merger agreement includes a termination fee of about $155.5 million payable by Catalyst to Angelini in specified circumstances, including acceptance of a superior proposal. Catalyst’s directors and executive officers signed voting agreements to support the deal. Separately, Catalyst and SERB settled patent litigation with Hetero over generic FIRDAPSE®, with Hetero barred from U.S. sales of its generic before January 2035, resolving all pending FIRDAPSE patent cases.
Catalyst Pharmaceuticals, Inc. filed Amendment No. 1 to its 2025 annual report to include Part III information on directors, executive officers, corporate governance, executive compensation, security ownership, and auditor fees. The company confirms the amendment adds no new financial statements and does not change previously reported results.
The filing details 2025 pay-versus-performance data, showing net product revenue of $588.8 million and net income of $214.3 million, and discloses a 2025 CEO total compensation of $8.18 million with a CEO pay ratio of 26:1. It also describes the 2018 Stock Incentive Plan, including outstanding stock options and restricted stock units, and outlines governance policies such as the code of ethics, insider trading policy, and board committee structures.
Catalyst Pharmaceuticals Inc Schedule 13G/A amendment shows The Vanguard Group reports zero beneficial ownership of Common Stock as of the filing, with 0 shares and 0% of the class. The amendment notes an internal realignment at Vanguard and that certain subsidiaries now report ownership separately in reliance on SEC Release No. 34-39538.